Luis Manrique Trujillo, MD
Neurology · Washington, DCNPI 1184101495
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by EMD Serono, Inc. at 58.5% of the total.
Across 153 payments — averaging $179.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$16K
- Sanofi$4K
- Genentech USA, Inc.$4K
- Biogen$787
- Novartis$507
- TG Therapeutics, Inc.$341
- plus $2K from 14 others
What the payments were for
- Consulting fees$9,60935%
- Speaking & faculty fees$6,00022%
- Travel & lodging$4,20715%
- Food & beverage$7,07326%
- Education$5212%
- Gifts$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 42 | $16,071 |
| Sanofi | 22 | $4,476 |
| Genentech USA, Inc. | 8 | $3,686 |
| Biogen | 21 | $787 |
| Novartis | 20 | $507 |
| TG Therapeutics, Inc. | 4 | $341 |
| Genentech, Inc. | 4 | $309 |
| Amgen | 8 | $293 |
| E.r. Squibb & Sons, L.L.C. | 2 | $266 |
| AstraZeneca | 5 | $255 |
| Eisai Inc. | 6 | $188 |
| Medtronic | 1 | $71 |
| AbbVie | 2 | $44 |
| Bristol Myers Squibb | 2 | $42 |
| Argenx US, Inc. | 1 | $28 |
| UCB, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,489 in reported general payments places this provider in the 80th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 35 | $321,287 |
| Teriflunomide | 11 | $32,178 |
| Dimethyl Fumarate | 12 | $28,238 |
| Baclofen | 41 | $1,136 |
| Duloxetine Hcl | 22 | $838 |
| Pregabalin | 24 | $659 |
| Gabapentin | 21 | $297 |
| Zolpidem Tartrate | 11 | $13 |
Paid to pharmacies, not to this prescriber.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.